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Abstract
Introduction: Hepatitis C virus (HCV) and HIV infection frequently co-occur due to shared transmission routes. Co-infection is
associated with higher HCV viral load (VL), but less is known about the effect of HCV infection on HIV VL and risk of onward
transmission.
Methods: We undertook a systematic review comparing 1) HIV VL among ART-naı¨ve, HCV co-infected individuals versus HIV
mono-infected individuals and 2) HIV VL among treated versus untreated HCV co-infected individuals. We performed a random-
effects meta-analysis and quantified heterogeneity using the I2 statistic. We followed Cochrane Collaboration guidelines in
conducting our review and PRISMA guidelines in reporting results.
Results and discussion: We screened 3925 articles and identified 17 relevant publications. A meta-analysis found no evidence of
increased HIV VL associated with HCV co-infection or between HIV VL and HCV treatment with pegylated interferon-alpha-2a/b
and ribavirin.
Conclusions: This finding is in contrast to the substantial increases in HIV VL observed with several other systemic infections. It
presents opportunities to elucidate the biological pathways that underpin epidemiological synergy in HIV co-infections and may
enable prediction of which co-infections are most important to epidemic control.
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Introduction
Approximately 2.3 million people worldwide are infected with
both HIV and hepatitis C virus (HCV) [1]. HIV infection is asso-
ciated with increased HCV replication, and co-infected patients
have higher HCV viral load (VL) compared to theirmono-infected
counterparts [2]. Additionally, the risk of mother-to-child
transmission of HCV infection is nearly twofold higher in HIV-
HCV co-infected women than in HCV mono-infected women.
Furthermore, the risk of cirrhosis or liver failure is higher in
co-infected individuals as compared to those with either HCV
or HIV mono-infection [3,4]. However, less is known about
the effect of HCV on HIV VL and onward transmission. Other
HIV co-infections such as acute malaria, herpes simplex 2, and
tuberculosis increase HIV VL [5], likely through inflammatory-
mediated mechanisms. HIV VL is the key determinant of HIV
transmission [6,7] and, consequently, these HIV co-infections
have the potential to increase the probability of HIV trans-
mission through significant increases in VL.
New HCV treatment options provide opportunities for
sustained virological response over a short duration of therapy
(8 to 12 weeks) with a high success rate (90%), including
among HIV co-infected persons [811]. However, the majority
of the 130 to 150 million people living with HCV worldwide
are unaware of their infection and do not have access to
treatment [1214]. If HCV co-infection increases HIV VL and
consequently HIV transmission and progression, HCV diag-
nosis and treatment programmes could potentially decrease
HIV incidence at the population level, in addition to decreasing
HCV incidence and prevalence. HCV treatment programmes
that do not account for this additional health benefit would
underestimate the cost-effectiveness of HCV treatment.
Results of studies looking at the effect of HCV co-infection
on HIV VL are mixed. Some observational studies reported
higher HIV VL in co-infected persons [15], whereas others
found no effect on HIV VL [16], and still others reported lower
HIV VL in co-infected persons [17]. Notably, the majority of
studies have been conducted in populations being treated
with antiretroviral therapy (ART). A recent systematic review
and meta-analysis of the impact of HCV on immunological
and virological responses after ART initiation suggested an
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adverse effect of HCV on immune recovery of HIV-infected
individuals initiating ART, especially among those with
initially impaired immunological status (CD4 count below
350 cells/mm3) [18]. To our knowledge, the effect of HCV
co-infection on HIV VL among ART-naı¨ve individuals has not
been systematically reviewed. In low- and middle-income
countries, nearly 60% of the 34.4 million people living
with HIV lack access to ART [19]. Therefore, understanding
the impact of HCV and its treatment on HIV infection is
particularly relevant in this underserved population.
We hypothesize that HCV co-infection increases HIV VL
through inflammatory-mediated mechanisms. To address this
question, we reviewed the evidence and conducted a meta-
analysis for an association of HCV co-infection and treatment
with HIV-related outcomes among ART-naı¨ve patients.
Methods
We followed Cochrane Collaboration guidelines in conducting
our review [20] and PRISMA guidelines in reporting results
[21].
Study objectives and criteria for considering studies
for this review
The six study objectives were to assess the impact of
1) untreated HCV infection on HIV-1 VL; 2) HCV treatment
on HIV-1 VL; 3) untreated HCV infection on HIV-1 transmission
in HIV-1 serodiscordant couples; 4) HCV treatment on HIV-1
transmission in HIV-1 serodiscordant couples; 5) untreated
HCV infection on HIV-1 acquisition; and 6) HCV treatment
on HIV-1 acquisition.
Observational epidemiological studies and randomized
controlled trials were eligible. Studies that included the
following participants were excluded from the review: parti-
cipants aged 12 years or younger, patients on HIV treatment,
pregnant women and HIV-2 infected patients. In addition,
patients on HCV treatment were excluded from Objectives
1, 3 and 5. For studies in which a subgroup of participants did
not meet the inclusion criteria, results were extracted for
eligible participants if studies allowed for this (e.g. if results
were stratified by ART status).
Search strategy for identification of studies
Electronic searches of the PubMed and Embase databases
were conducted on 30 July 2013 and updated on 11 February
2015. The following search was conducted in PubMed: ((HCV
[MeSH Terms]) OR HCV [Text Word] OR HCV [Text Word]) AND
(human immunodeficiency virus [MeSH Terms] OR human
immunodeficiency virus [Text Word] OR HIV [Text Word] OR
acquired immune deficiency syndrome [MeSH Terms]) AND
(‘‘Epidemiologic Studies’’ [MeSH] OR ‘‘clinical trials as topic’’
[MeSH]).
A similar search that excluded articles indexed in PubMed
was conducted in Embase using the following search terms:
((‘‘hepatitis’’/exp OR ‘‘hepatitis’’/de AND c AND (‘‘virus’’/exp
OR ‘‘virus’’/de)) OR hcv) AND ((‘‘human’’/exp OR ‘‘human’’/
de) AND (‘‘immunodeficiency’’/exp OR ‘‘immunodeficiency’’/
de) AND (‘‘virus’’/exp OR ‘‘virus’’/de)) OR ‘‘HIV’’/exp OR
‘‘HIV’’/de OR (acquired AND immune AND deficiency AND
(‘‘syndrome’’/exp OR ‘‘syndrome’’/de)) NOT [medline]/lim
AND ([adolescent]/lim OR [adult]/lim OR [aged]/lim) AND
[humans]/lim AND [embase]/lim. Search results were collated
using the reference manager EndNote (Thomson Reuters,
New York, NY, USA) to identify any remaining duplicate citations.
The searches included all languages and were limited to
studies in humans. The search was not restricted by specified
start or end dates and ran through the date on which
the updated search was conducted on 11 February 2015.
Reference lists of papers meeting criteria were hand searched
for additional articles. Abstracts were reviewed from the
past three meetings of the Conference on Retroviruses and
Opportunistic Infections, the International Symposium on
HCV and Related Viruses, ID Week/Infectious Disease Society
of America, the International Liver Congress/EASL and the
Liver Meeting/AASLD.
Selection of studies, data extraction and synthesis
Abstracts were reviewed and full-text articles of potentially
relevant studies were reviewed independently by two authors
(NEP and RVB, HAW or JNW) against predefined criteria. Data
were extracted by NEP and JMR, using a standardized data
extraction form. Discrepancies were discussed and consensus
reached. Authors were contacted for papers that reported
that they had gathered data of interest but did not present
these data in the text or did not completely report all results
and statistics.
When data from the same individuals were reported in
multiple publications, we used the publication that incorpo-
rated the most relevant data or most comprehensive analysis.
Publications with overlapping cohorts were considered on
a case-by-case basis. We estimated CIs based on standard
deviations reported or displayed in the articles.
The methodological quality of included studies was re-
viewed by NEP and JMR using a tool to record the confounding
variables assessed in the study. Discrepancies in quality rating
were discussed and consensus reached. Studies were rated
as low, moderate or high risk of bias. A key factor was how
studies accounted for time since HIV seroconversion, because
VL is dynamic and changes over time. Adjustment for CD4 and
sociodemographic variables was also considered. If these
factors were handled appropriately in the design and analysis,
studies that reported HIV VL stratified by CD4 count were
generally rated as low risk of bias. In contrast, studies that
reported and compared the mean CD4 counts of each group
were rated as medium risk. Studies that did not adjust for
CD4 count were rated as high risk.
Statistical methods
The primary outcome of interest was the mean log10 HIV
VL difference between HIV-HCV co-infected and HIV mono-
infected individuals for Objective 1 and by HCV treatment
status for Objective 2. Meta-analysis was performed using
the DerSimonian and Laird method for random effects and
implemented with the ‘‘metan’’ command in Stata. Hetero-
geneity was quantified using the I2 statistic. Funnel plots
were visually examined and Egger tests were conducted to
assess the possibility of publication bias. All statistical analyses
were conducted in STATA version 13 (StataCorp, College
Station, TX, USA).
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Results and discussion
A total of 17 studies were included out of 3925 articles and
abstracts that were screened (Figure 1). Overall, the three
most common reasons for exclusion were the patients having
received ART, inappropriate comparison group and primary
outcomes that were not relevant for this analysis. Of the 17
articles identified, 15 addressed the impact of HCV infection
on HIV VL (Objective 1) [4,1517,2232], whereas two
studies [33,34] examined the impact of HCV treatment on
HIV VL (Objective 2). Because no studies were identified that
addressed the other four objectives, this article describes
results of the review and meta-analysis of Objectives 1 and 2.
Objective 1: Impact of HCV infection on HIV viral load
Details of the 15 studies eligible for Objective 1 are shown
in Table 1. The studies were conducted in China, Europe,
Africa and North America. Two studies were cross-sectional
[25,32], whereas the remainder were longitudinal in design
(nine prospective [4,15,17,22,23,26,27,30,31], three retro-
spective [16,28,29] and one case control [24]). The quality
of the studies varied, and adjustment for confounders was
conducted in only five studies. Three of the studies were
assessed as low risk of bias [22,23,28], three with a medium
risk [4,16,26] and the remainder with a high risk of bias
[15,17,24,25,27,2932]. Data included in the meta-analysis
evaluated HIV VL at a single time point. The studies ranged
in size from 16 [24] to 1510 [28] participants.
The studies varied in whether they used the presence
of HCV RNA or HCV antibody to classify participants’ HCV
infection status. Three studies considered separately those
who had a positive HCV antibody without detectable RNA
versus those who were also viremic, finding that 12 to 18%
of antibody-positive patients had undetectable HCV RNA
[22,23,26]. Two studies only included co-infected participants
with detectable HCV RNA [24,25]. One study tested for
HCV RNA in subjects who were HCV antibody positive but
did not clearly restrict its analysis to participants with HCV
viremia [29]. Eight studies classified participants based on
HCV antibody testing alone without RNA confirmation of
active viremia [4,1517,27,3032]. The final study classified
HCV infection based on diagnosis codes from the medical
record [28]. None of the studies reported testing for HCV
RNA in those participants with a negative HCV antibody.
Only four studies found strong evidence of association
(pB0.05) between HIV-HCV co-infection and HIV VL, with all
four pointing towards higher HIV VL among mono-infected
patients than among co-infected patients [17,22,29,30]. The
majority of the studies revealed no significant association.
Fourteen of the fifteen studies were included in the meta-
analysis (Figure 2) [4,1517,2332]. There was evidence
of moderate heterogeneity in effect size between studies
(I256.8%; p0.005). The summary estimate of the
mean difference between VL in the co-infected vs mono-
infected was 0.06 log10 copies/mL (95% CI: 0.14, 0.01;
Figure 1. PRISMA flow diagram of studies included in systematic review.
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Table 1. Studies included in the systematic review for Objective 1
HIV/HCV co-infecteda HIV mono-infected
First author Data collection Location Study design Population N
Mean log10 HIV
viral load (95% CI)b N
Mean log10 HIV
viral load (95% CI)b
Zhang 1992 to 1995 China Retrospective cohortc Former blood donors 135 4.15 (4.05 to 4.25) 20 4.43 (4.18 to 4.68)
Li NA China Prospective cohortc Research centres 58 4.43 (3.71 to 5.15) 117 4.47 (3.83 to 5.11)
Liang 1994 to 2006 Taiwan Retrospective cohortd IDUs at referral hospital 79 4.55 (4.40 to 4.70) 9 5.04 (4.61 to 5.47)
Filippini 1996 to 2001 Italy Prospective cohortd HIV-infected persons 24 4.84 (2.76 to 6.92) 36 4.45 (2.78 to 6.11)
Filippini NA Italy Case control 8 4.50 (4.01 to 4.99) 8 4.26 (4.07 to 4.45)
Antonucci 1997 to 2004 Italy Prospective cohortd Italian Cohort Naı¨ve for Antiretrovirals 156e 4.77 (2.60 to 6.53)f 1219 4.91 (1.30 to 6.88)f
Braitstein 1996 to 2003 Canada Retrospective cohortc HIV/AIDS Drug Treatment Programme 606 4.74 (4.70 to 4.77) 580 4.72 (4.68 to 4.76)
Rockstroh 1994 to 2003 Argentina, Europe, Israel Prospective cohortd EuroSIDA cohort 202 4.26 (4.13 to 4.38) 428 4.23 (4.14 to 4.32)
Kovacs 1994 to 1995 USA Prospective cohortc Women’s Interagency HIV Study 215g 3.92 (3.80 to 4.04) 331 4.05 (3.95 to 4.15)
Cheng NA USA Prospective cohortc People with alcohol problems living with HIV 100 2.59 (2.28 to 2.90) 110 2.82 (2.31 to 3.11)
Ko¨rner NA Germany Cross sectional 14 4.66 (2.65 to 5.74) 25 4.60 (1.70 to 5.58)
Sullivan 1998 to 2004 USA Prospective cohortc Adult and Adolescent Spectrum of HIV Disease 269 4.93 (4.86 to 5.00) 1241 4.92 (4.88 to 4.95)
Lodwick 1990 to 2004 Europe Prospective cohortc Swiss HIV Cohort Study with CD4350h 569 3.97 (3.87 to 4.07) 605 4.23 (4.15 to 4.31)
Greub 1996 to 2000 Europe Prospective cohortc Swiss HIV Cohort Study 476 4.64 (4.55 to 4.73) 932 4.62 (4.56 to 4.68)
Salpini 2010 Cameroon Cross sectional HIV-infected persons 18 4.63 (3.99 to 5.27) 52 4.60 (4.24 to 4.96)
aHCV test by antibody only for Zhang, Li, Filippini 2003, Rockstroh, Lodwick, Braitstein, Greub and Salpini; by HCV RNA for Liang, Filippini 2000, Antonucci, Kovacs, Cheng and Korner; bHIV RNA test by
polymerase chain reaction (PCR) for Filippini 2000, Filippini 2003, Liang, Zhang, Greub and Salpini; by branched DNA (bDNA) for Li; by either PCR or bDNA for Cheng and Korner; by nucleic acid sequence
based amplification for Kovacs; or method not specified in publication for Antonucci, Braitstein, Lodwick, Rockstroh and Sullivan; cdata from follow-up; ddata from baseline; epatients with an HCV RNA load
above 1106 IU/mL; fmedian and range; gincludes patients with HCV viremia and aviremic patients; hcohort used in this analysis excludes patients who were included in the Greub study. HCV, hepatitis C
virus; NA, not applicable.
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p0.09). The study not included in the meta-analysis
was one in which only the median HIV VLs were given
(4.77 log10 copies/mL in co-infected individuals with an HCV
VL above 1106 IU per mL, 4.70 log10 copies/mL in co-
infected individuals with an HCV VL 5.1106 IU per mL and
4.91 log10 copies/mL in mono-infected; p0.01) [22].
A post hoc analysis of studies that only included patients
with HCV viremia in the HIV-HCV co-infection arm [2326,29]
also found no difference in HIV VL between co-infected and
HIV mono-infected patients (Figure 1; Supplementary file).
Objective 2: Impact of HCV treatment on HIV viral load
Only two studies reported outcomes of interest for
Objective 2 [33,34]. The studies found different effects of
HCV therapy with pegylated interferon-alpha-2a/b and
ribavirin on HIV VL. In the Obermeier et al. study, treatment
was associated with an increased mean HIV VL of 4.52 log10
copies vs 4.14 log10 copies in untreated individuals (no
confidence intervals provided). In the COHERE study, HIV VL
decreased from 4.20 (95% CI (3.31, 5.09)) at enrolment in the
study to 4.00 (95% CI (3.09, 4.91)) 12 weeks after the start of
HCV treatment. However, both studies found that treatment
with pegylated interferon-alpha-2a/b and ribavirin had no
statistically significant impact on HIV VL (Obermeier et al.:
p0.61; COHERE: p0.17).
Discussion
The principal finding from this study is that patients co-
infected with HIV and HCV do not have significantly higher
HIV VL than patients with HIV who are HCV-uninfected. The
subset of studies that restricted their analysis to patients
with documented HCV viremia found either no significant
(pB0.05) difference in HIV VL between HIV mono-infected
and HIV/HCV co-infected participants [2326] or significantly
lower HIV VL in the co-infected population [22,29].
The finding is interesting for several reasons. First, patients
co-infected with HIV and other pathogens, including herpes
simplex virus, malaria and tuberculosis, exhibit significantly
higher levels of HIV RNA in the blood [5]. Second, HCV
infection does affect other markers of HIV disease progres-
sion such as inhibiting CD4 count recovery [18,35,36]. Third,
the relationship between HIV and HCV VL is non-reciprocal:
other studies have shown that HIV co-infection increases HCV
VL in subjects by increasing the rate of viral replication [37]
and immune suppression, as well as accelerating liver disease
progression [3]. The surprising lack of association between
Figure 2. Random-effects meta-analysis of the mean difference in HIV viral load (log10 copies/mL) between HIV/HCV co-infected and HIV
mono-infected individuals.
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HCV infection and HIV VL offers an opportunity to further
explore the different mechanisms underpinning interactions
between HIV and HCV compared with those underpinning
interactions between HIV and other pathogens that result in
persistent, systemic infections.
Co-infection with HIV and tuberculosis, malaria and
herpes simplex virus results in higher HIV VL through multiple
pathways that affect the equilibrium between HIV viral
replication and control of the virus by the host immune
system. Many efforts to understand HIV replication focus on
the transcriptional promoter for the HIV-1 genome, which lies
within the long terminal repeat that encodes the transactiva-
tion response element [38]. This promoter interacts with the
viral transcriptional activator protein tat, which is necessary
for viral replication [39,40] and operates in conjunction with
several host transcriptional co-factors. Cytokines such as
tumour necrosis factor alpha (TNF-a), interleukin (IL)-1b and
IL-6 also affect viral replication [41]. Co-infecting pathogens
increase HIV viral replication through de-repression of the
transcriptional promoter (active tuberculosis) [42,43], activa-
tion by antigen presenting cells and increase in TNF-a
secretion (malaria) [4446], and transcriptional activation
and cytokine release (HSV-2) [47,48].
The relationship between hepatitis B virus (HBV) infection
and HIV VL demonstrates similarities with the mechanisms
activated by the co-infecting pathogens described above.
HBV X protein induces transcription of the HIV genome by
synergizing with tat protein [49]. To our knowledge, the
effect of HBV status on HIV VL has not been systematically
reviewed, but observational studies in several settings indi-
cate mixed results. Ladep and colleagues and Idoko and
colleagues found a significantly higher HIV VL among ART-
naı¨ve Nigerian patients with HIV-HBV co-infection than among
HIV mono-infected patients [50,51]. In contrast, Hoffmann
and colleagues found no difference in HIV VL by HBV infection
status in a large study of South Africans initiating ART [52].
We may expect HCV infection to increase HIV VL because,
in vitro, HCV has been shown to induce transcription of the
HIV-1 genome [53]. However, as we did not find an increased
HIV VL among those with HCV co-infection, we propose
several alternate hypotheses for evaluation. One hypothesis
is that since the burden of HCV infection is in the liver, HCV
may not be available to interact with HIV at the major site of
HIV replication in the lymphoid tissues. Despite this, HCV
infection has been reported to occur in the human peripheral
blood mononuclear cells that are the primary site of HIV
infection and in these sites is associated with increases in
TNF-a and IL-8 [54,55]. Additionally, in vitro, endocytosis of
HCV and HIV virions by blood monocytes or plasmacytoid
dendritic cells can induce production of interferon [56] or IL-8
as well as activation of the NLRP3 inflammasome to produce
and release IL1-b without requiring a productive infection of
the cell itself [57]. A second hypothesis is that inflammasome
induction by HCV may limit HIV replication in co-infected
cells, which may mask an inflammation-induced increase in
HIV VL occurring in cells without HCV infection (M Gale, pers.
commun., 9 October 2015). A third hypothesis is that co-
infecting pathogens such as herpes simplex virus that result
in episodes of symptomatic or asymptomatic reactivation
episodes or pathogens causing repeated bouts of infection,
as with malaria, may cause more of a systemic inflammatory
response. Finally, there may be characteristics of the HIV-1
strains associated with particular modes of transmission,
such as intravenous drug use, that confound the relationship
between HCV infection status and HIV VL [58].
Notably, study limitations may have precluded detection of
a difference between HIV VL in mono-infected patients and
those with HIV-HCV co-infection. The quality of the studies,
including the methods used to control for potential con-
founders, varied substantially between the studies, and this is
likely to have contributed to the statistical heterogeneity
between study results. Some did not control for any potential
confounders, while others controlled extensively for patient
characteristics that might influence VL levels, including CD4
counts, age, ethnicity, HIV-1 clade and mode of HIV transmis-
sion. Additionally, this systematic review found a dearth of
high quality studies on the impact of HCV infection on HIV
acquisition and transmission, as well as on the impact of HCV
treatment on HIV infection, acquisition and transmission
(Objectives 3 to 6). This is due in part to the fact that the
search criteria excluded studies and patients experienced with
ART for HIV, which was done because of the effectiveness of
ART in decreasing HIV VL. As expected, very few studies from
the mid-1990s onwards could be included because very few
patients were ART-naı¨ve. Even in the included studies that
enrolled ART-naı¨ve participants, the majority reported a single
baseline HIV VL prior to ART administration. Thus, an
additional limitation in the existing literature is that it does
not permit conclusions about the interaction between HIV
and HCV over time.
Bidirectional misclassification of active HCV status due to
HCV antibody testing may have limited the ability of these
studies to detect an effect of HCV infection on HIV VL.
Whereas nearly half of the studies used HCV RNA testing
to confirm active infection in patients who were antibody
positive, the remainder did not, which allows for the
possibility that patients who had cleared their HCV infection
or who had a biological false positive test, such as from an
autoimmune disease, may have been incorrectly classified
as having HCV. Despite this potential misclassification, a post
hoc meta-analysis of studies that only included participants
with HCV viremia in the HCV infection arm found no
difference in HIV VL between HIV-HCV co-infected persons
and persons with HIV mono-infection. The potential for
misclassification in the other direction exists as well due to
an increased risk for lack of anti-HCV antibody in chronically
HCV-infected patients who are immunocompromised due
to HIV infection [59]. However, the magnitude of this effect
would likely be small; only approximately 5% of HIV-positive
patients who are HCV antibody negative have been found to
have detectable serum HCV RNA [59,60].
Conclusions
In our systematic review, HCV infection was not associated
with an increase in HIV VL among adults with HIV infection.
This is in contrast to the substantial increases in HIV VL
observed with several other systemic infections. Indeed, HCV
infection appears to resemble HPV infection in that HIV
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accelerates progression of HCV disease without a reciprocal
effect of HCV on HIV VL. Comparative analyses of the
biological mechanisms underpinning HCV-HIV interactions
and those responsible for interactions between HIV and other
persistent or frequently recurrent infections such as herpes,
malaria, TB and HPV offer critical opportunities to elucidate
the complex pathways that lead to epidemiological synergy.
Such analyses may ultimately enable us to predict which
co-infections are most likely to accelerate the spread of HIV
through populations and, conversely, which are most likely
to have their own natural history or response to therapy
adversely affected by HIV. Equally important, with the on-
going, rapid evolution of effective HCV therapies, HCV testing
among HIV-infected individuals is recommended and should
be aggressively implemented because of the increased rate
of progression of liver disease in this population.
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